Aquellos que tienen la suerte de vivir en un país donde el uso de cannabis es legal, se podrán encontrar con distintos tipos de aceite dependiendo de qué cannabinoide esté en mayor concentración. El aceite de CBD tendrá principalmente cannabidiol, el cannabinoide no psicoactivo y muy útil en los casos de epilepsia. También podrán encontrar aceite con un mayor concentración de THC, el cannabinoide psicoactivo, útil para los dolores, aumento del apetito, nauseas y vómitos por la quimioterapia, etc. Será el mismo usuario junto a un especialista el que deberá determinar qué tipo de aceite y concentración será útil en cada caso.
A. The FDA is aware that several states have either passed laws that remove state restrictions on the medical use of marijuana and its derivatives or are considering doing so. It is important to conduct medical research into the safety and effectiveness of marijuana products through adequate and well-controlled clinical trials. We welcome the opportunity to talk with states who are considering support for medical research of marijuana and its derivatives to provide information on Federal and scientific standards.
One of CBD’s chief properties is its anticonvulsant nature. Clinical trials have shown that CBD is effective at reducing seizures in children, and the FDA is likely to approve Epidiolex, a pharmaceutical-grade version of CBD for this use, in summer 2018. Although CBD has been documented as an antiepileptic since 1881, CBD’s anticonvulsant mechanisms still remain unclear. Not enough studies have been conducted to understand this relationship fully. One possible explanation for CBD’s neuroprotective effects is its interaction with NMDA receptors, which play a key role in the overly active neuron activity that is a hallmark of epilepsy.